{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:48:47Z","timestamp":1785826127937,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-026-03090-9","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:05:50Z","timestamp":1770282350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["miR-194-5p targets SOCS2 to predict pegIFN\u03b1 treatment response in HBeAg-positive chronic hepatitis B patients"],"prefix":"10.1186","volume":"23","author":[{"given":"Yanling","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"LijuanZhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"3090_CR1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546\u201355.","journal-title":"Lancet"},{"key":"3090_CR2","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053\u201363.","journal-title":"Lancet"},{"key":"3090_CR3","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"GA Kim","year":"2014","unstructured":"Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325\u201332.","journal-title":"Gut"},{"key":"3090_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr., Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"3090_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4:545\u201358.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3090_CR6","doi-asserted-by":"crossref","unstructured":"EASL. 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017, 67:370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"3090_CR7","doi-asserted-by":"publisher","first-page":"1474342","DOI":"10.3389\/fphar.2024.1474342","volume":"15","author":"X Zhang","year":"2024","unstructured":"Zhang X, Yang X, Tan L, Tian Y, Zhao Z, Ru S. The efficacy and safety of addition of pegylated interferon to long-term nucleos(t)ide analogue therapy on functional cure of chronic hepatitis B patient: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1474342.","journal-title":"Front Pharmacol"},{"key":"3090_CR8","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3748\/wjg.v26.i11.1113","volume":"26","author":"DG Iacob","year":"2020","unstructured":"Iacob DG, Rosca A, Ruta SM. Circulating microRNAs as non-invasive biomarkers for hepatitis B virus liver fibrosis. World J Gastroenterol. 2020;26:1113\u201327.","journal-title":"World J Gastroenterol"},{"key":"3090_CR9","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.3748\/wjg.v29.i31.4706","volume":"29","author":"MH Zhang","year":"2023","unstructured":"Zhang MH, Yuan YF, Liu LJ, Wei YX, Yin WY, Zheng LZ, et al. Dysregulated microRNAs as a biomarker for diagnosis and prognosis of hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2023;29:4706\u201335.","journal-title":"World J Gastroenterol"},{"key":"3090_CR10","first-page":"134","volume":"12","author":"S Liu","year":"2024","unstructured":"Liu S, Xie J, Duan C, Zhao X, Feng Z, Dai Z, Luo X, Li Y, Yang M, Zhuang R, et al. ADAR1 inhibits macrophage apoptosis and alleviates Sepsis-induced liver injury through miR-122\/BCL2A1 signaling. J Clin Transl Hepatol. 2024;12:134\u201350.","journal-title":"J Clin Transl Hepatol"},{"key":"3090_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3892\/etm.2020.9600","volume":"21","author":"W Li","year":"2021","unstructured":"Li W, Yu X, Chen X, Wang Z, Yin M, Zhao Z, Zhu C. HBV induces liver fibrosis via the TGF-\u03b21\/miR-21-5p pathway. Exp Ther Med. 2021;21:169.","journal-title":"Exp Ther Med"},{"key":"3090_CR12","doi-asserted-by":"publisher","first-page":"e65336","DOI":"10.1371\/journal.pone.0065336","volume":"8","author":"N Coppola","year":"2013","unstructured":"Coppola N, Potenza N, Pisaturo M, Mosca N, Tonziello G, Signoriello G, et al. Liver microrna hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One. 2013;8:e65336.","journal-title":"PLoS One"},{"key":"3090_CR13","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/infdis\/jix140","volume":"215","author":"MH van der Ree","year":"2017","unstructured":"van der Ree MH, Jansen L, Kruize Z, van Nuenen AC, van Dort KA, Takkenberg RB, Reesink HW, Kootstra NA. Plasma MicroRNA levels are associated with hepatitis B e antigen status and treatment response in chronic hepatitis B patients. J Infect Dis. 2017;215:1421\u20139.","journal-title":"J Infect Dis"},{"key":"3090_CR14","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1002\/jmv.26916","volume":"93","author":"Q Hu","year":"2021","unstructured":"Hu Q, Wang Q, Zhang Y, Tao S, Zhang X, Liu X, Li X, Jiang X, Huang C, Xu W, et al. Baseline serum exosome-derived MiRNAs predict hbeag seroconversion in chronic hepatitis B patients treated with peginterferon. J Med Virol. 2021;93:4939\u201348.","journal-title":"J Med Virol"},{"key":"3090_CR15","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jvh.13126","volume":"26","author":"Q Ning","year":"2019","unstructured":"Ning Q, Wu D, Wang GQ, Ren H, Gao ZL, Hu P, Han MF, Wang Y, Zhang WH, Lu FM, Wang FS. Roadmap to functional cure of chronic hepatitis B: an expert consensus. J Viral Hepat. 2019;26:1146\u201355.","journal-title":"J Viral Hepat"},{"key":"3090_CR16","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/hep.26436","volume":"58","author":"MJ Sonneveld","year":"2013","unstructured":"Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology. 2013;58:872\u201380.","journal-title":"Hepatology"},{"key":"3090_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","volume":"32","author":"WM Schneider","year":"2014","unstructured":"Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513\u201345.","journal-title":"Annu Rev Immunol"},{"key":"3090_CR18","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jhep.2014.10.004","volume":"62","author":"S Bandiera","year":"2015","unstructured":"Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122\u2013a key factor and therapeutic target in liver disease. J Hepatol. 2015;62:448\u201357.","journal-title":"J Hepatol"},{"key":"3090_CR19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1261\/rna.048744.114","volume":"21","author":"JY Huang","year":"2015","unstructured":"Huang JY, Chou SF, Lee JW, Chen HL, Chen CM, Tao MH, Shih C. MicroRNA-130a can inhibit hepatitis B virus replication via targeting PGC1\u03b1 and PPAR\u03b3. RNA. 2015;21:385\u2013400.","journal-title":"RNA"},{"key":"3090_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/1743-422X-8-354","volume":"8","author":"C Su","year":"2011","unstructured":"Su C, Hou Z, Zhang C, Tian Z, Zhang J. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol J. 2011;8:354.","journal-title":"Virol J"},{"key":"3090_CR21","first-page":"238","volume":"68","author":"S Jiang","year":"2025","unstructured":"Jiang S, Bai Z, Li J, Zhou N. CircERBB3 targets miR-194-5p\/PRMT3 to promote hepatocellular carcinoma progression. J Physiol Invest. 2025;68:238\u201347.","journal-title":"J Physiol Invest"},{"key":"3090_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1128\/JVI.01710-12","volume":"87","author":"J Hao","year":"2013","unstructured":"Hao J, Jin W, Li X, Wang S, Zhang X, Fan H, Li C, Chen L, Gao B, Liu G, Meng S. Inhibition of alpha interferon (IFN-\u03b1)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-\u03b1. J Virol. 2013;87:137\u201347.","journal-title":"J Virol"},{"key":"3090_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1089\/gtmb.2018.0092","volume":"23","author":"J Fang","year":"2019","unstructured":"Fang J, Zhuge L, Rao H, Huang S, Jin L, Li J. Increased levels of miR-155 are related to higher T-cell activation in the peripheral blood of patients with chronic hepatitis B. Genet Test Mol Biomarkers. 2019;23:118\u201323.","journal-title":"Genet Test Mol Biomarkers"},{"key":"3090_CR24","doi-asserted-by":"publisher","unstructured":"Duan X, Li S, Holmes JA, Tu Z, Li Y, Cai D, et al. <Emphasis Type=\"Bold\">MicroRNA 130a regulates both hepatitis C virus and hepatitis B virus replication through a central metabolic pathway.<\/Emphasis>. J Virol. 2018. https:\/\/doi.org\/10.1128\/JVI.02009-17.","DOI":"10.1128\/JVI.02009-17"},{"key":"3090_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.antiviral.2006.05.006","volume":"72","author":"T Zhou","year":"2006","unstructured":"Zhou T, Guo H, Guo JT, Cuconati A, Mehta A, Block TM. Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a CccDNA surrogate in antiviral screening assays. Antiviral Res. 2006;72:116\u201324.","journal-title":"Antiviral Res"},{"key":"3090_CR26","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","volume":"41","author":"SK Ladner","year":"1997","unstructured":"Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother. 1997;41:1715\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"3090_CR27","doi-asserted-by":"publisher","unstructured":"Huang Q, Cai D, Yan R, Li L, Zong Y, Guo L, et al. <Emphasis Type=\"Bold\">Preclinical profile and characterization of the hepatitis B virus core protein inhibitor ABI-H0731.<\/Emphasis>. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/AAC.01463-20.","DOI":"10.1128\/AAC.01463-20"},{"key":"3090_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/infdis\/jiaf102","volume":"232","author":"H Yu","year":"2025","unstructured":"Yu H, Li B, Guo H, Li L, Liu X, Wu L, et al. SLC22A1 resists hepatitis B virus by activating the JAK\/STAT pathway and predicts the effect of pegylated interferon \u03b1-based therapy on chronic hepatitis B. J Infect Dis. 2025;232:474\u201384.","journal-title":"J Infect Dis"},{"key":"3090_CR29","doi-asserted-by":"publisher","first-page":"e14292","DOI":"10.1111\/ijcp.14292","volume":"75","author":"M Bek\u00e7iba\u015f\u0131","year":"2021","unstructured":"Bek\u00e7iba\u015f\u0131 M, Deveci \u00d6, O\u011fuz A, Bozkurt F, Dayan S, \u00c7elen MK. Serum TNF-\u03b1, IL-1\u03b2, and IL-6 levels in chronic HBV-infected patients. Int J Clin Pract. 2021;75:e14292.","journal-title":"Int J Clin Pract"},{"key":"3090_CR30","doi-asserted-by":"publisher","first-page":"e00935","DOI":"10.1002\/mgg3.935","volume":"7","author":"A Woziwodzka","year":"2019","unstructured":"Woziwodzka A, Rybicka M, Sznarkowska A, Romanowski T, Dr\u0119czewski M, Stalke P, Bielawski KP. TNF-\u03b1 polymorphisms affect persistence and progression of HBV infection. Mol Genet Genomic Med. 2019;7:e00935.","journal-title":"Mol Genet Genomic Med"},{"key":"3090_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2217\/pme-2023-0089","volume":"20","author":"X Wang","year":"2023","unstructured":"Wang X, Gu X, Liu F. IL-6 gene polymorphism predicts pegylated IFN-\u03b1 treatment response in hepatitis B surface antigen-positive chronic hepatitis B patients. Per Med. 2023;20:503\u201310.","journal-title":"Per Med"},{"key":"3090_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jhep.2016.12.018","volume":"66","author":"X Yu","year":"2017","unstructured":"Yu X, Lan P, Hou X, Han Q, Lu N, Li T, et al. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1\u03b2 production via suppressing the NF-\u03baB pathway and ROS production. J Hepatol. 2017;66:693\u2013702.","journal-title":"J Hepatol"},{"key":"3090_CR33","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1089\/jir.2014.0161","volume":"35","author":"OO Onabajo","year":"2015","unstructured":"Onabajo OO, Porter-Gill P, Paquin A, Rao N, Liu L, Tang W, Brand N, Prokunina-Olsson L. Expression of interferon lambda 4 is associated with reduced proliferation and increased cell death in human hepatic cells. J Interferon Cytokine Res. 2015;35:888\u2013900.","journal-title":"J Interferon Cytokine Res"},{"key":"3090_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0014-5793(00)01905-0","volume":"480","author":"X Shen","year":"2000","unstructured":"Shen X, Hong F, Nguyen VA, Gao B. IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett. 2000;480:132\u20136.","journal-title":"FEBS Lett"},{"key":"3090_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41419-019-1530-4","volume":"10","author":"W Ren","year":"2019","unstructured":"Ren W, Wu S, Wu Y, Liu T, Zhao X, Li Y. MicroRNA-196a\/-196b regulate the progression of hepatocellular carcinoma through modulating the JAK\/STAT pathway via targeting SOCS2. Cell Death Dis. 2019;10:333.","journal-title":"Cell Death Dis"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03090-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03090-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03090-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:12:32Z","timestamp":1773058352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03090-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3090"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03090-9","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Suzhou Ninth People's Hospital. All participants provided written informed consent prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}